Vista Pharmaceuticals (524711) Q4 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 25/26 earnings summary
29 May, 2026Executive summary
Audited standalone financial results for the year ended March 31, 2026, and reviewed results for the quarter ended March 31, 2026, were presented and approved by the Board of Directors.
Statutory auditors issued an unmodified/unqualified opinion on the audited financial results for the year ended March 31, 2026.
Significant events and developments
Appointment of M/s. LMN & Co., Chartered Accountants, as Internal Auditor for the financial year 2026-27.
Risk factors and uncertainties
Auditors evaluated the appropriateness of the going concern basis and found no material uncertainty that would cast significant doubt on the company's ability to continue as a going concern.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Vista Pharmaceuticals
- Nil revenue, continued losses, and NPA status raise significant going concern risks.524711
Q1 26/27 - Q3 FY26 saw higher net loss and ECL provision, with statutory dues outstanding.524711Q3 25/26
- Q2 FY26 saw lower revenue, higher losses, and major ECL provisioning amid new capital raised.524711Q2 25/26
- Revenue fell and losses deepened in Q1 FY26, with leadership continuity affirmed.524711Q1 25/26
- Q2 FY25 saw lower revenue but reduced losses and stronger equity from capital raising.524711Q2 24/25
- Q1 FY25 saw lower revenue and a net loss, with AGM scheduled for September 30, 2024.524711Q1 24/25
- Net loss persists despite revenue growth; WHO certification and audit opinion boost credibility.524711Q4 24/25
- Q3 FY25 revenue surged, but losses continued; WHO certification marks a key milestone.524711Q3 24/25